Financials JD Health International Inc.

Equities

6618

KYG5074A1004

Drug Retailers

Market Closed - Hong Kong S.E. 09:08:22 29/04/2024 BST 5-day change 1st Jan Change
27.5 HKD +3.38% Intraday chart for JD Health International Inc. +17.02% -29.67%

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 402,020 159,955 200,382 113,318 78,525 - -
Enterprise Value (EV) 1 369,839 118,166 154,618 113,318 57,609 50,111 43,842
P/E ratio -16.2 x -143 x 525 x 52.3 x 32.7 x 24.8 x 19.3 x
Yield - - - - - - -
Capitalization / Revenue 20.7 x 5.21 x 4.29 x 2.12 x 1.26 x 1.08 x 0.94 x
EV / Revenue 19.1 x 3.85 x 3.31 x 2.12 x 0.93 x 0.69 x 0.52 x
EV / EBITDA 976 x -90.7 x 877 x 122 x 32.6 x 18 x 10.3 x
EV / FCF 101 x 40.5 x 26.4 x - 12.4 x 8.04 x 5.37 x
FCF Yield 0.99% 2.47% 3.79% - 8.08% 12.4% 18.6%
Price to Book 7.1 x 3.89 x 4.37 x - 1.49 x 1.37 x 1.25 x
Nbr of stocks (in thousands) 3,184,367 3,194,617 3,179,915 3,188,615 3,189,115 - -
Reference price 2 126.2 50.07 63.01 35.54 24.62 24.62 24.62
Announcement Date 29/03/21 28/03/22 22/03/23 20/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 10,842 19,383 30,682 46,736 53,530 62,111 72,716 83,929
EBITDA 1 - 378.9 -1,303 176.3 928.2 1,766 2,782 4,237
EBIT 1 - 351.7 -1,366 35.6 894.4 1,545 2,593 4,211
Operating Margin - 1.81% -4.45% 0.08% 1.67% 2.49% 3.57% 5.02%
Earnings before Tax (EBT) 1 - -17,072 -901.5 695.8 2,693 2,940 3,902 4,993
Net income 1 -971.8 -17,234 -1,074 380.1 2,142 2,410 3,184 4,113
Net margin -8.96% -88.92% -3.5% 0.81% 4% 3.88% 4.38% 4.9%
EPS 2 - -7.800 -0.3500 0.1200 0.6800 0.7533 0.9922 1.274
Free Cash Flow 1 - 3,662 2,921 5,865 - 4,656 6,237 8,161
FCF margin - 18.89% 9.52% 12.55% - 7.5% 8.58% 9.72%
FCF Conversion (EBITDA) - 966.35% - 3,327.11% - 263.63% 224.17% 192.61%
FCF Conversion (Net income) - - - 1,542.99% - 193.21% 195.85% 198.42%
Dividend per Share 2 - - - - - - - -
Announcement Date 25/11/20 29/03/21 28/03/22 22/03/23 20/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 Q2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 10,605 13,638 17,044 20,225 26,511 13,160 27,110 26,420 28,988 32,172
EBITDA - - -771.1 - - - - - - -
EBIT - 597.4 -808.5 1,201 -185.6 - 943.9 -243.2 - -
Operating Margin - 4.38% -4.74% 5.94% -0.7% - 3.48% -0.92% - -
Earnings before Tax (EBT) - - -556.2 377.3 318.5 - 1,831 862.1 - -
Net income - -454.2 -618.4 223 157.1 - 1,561 580.5 1,076 1,030
Net margin - -3.33% -3.63% 1.1% 0.59% - 5.76% 2.2% 3.71% 3.2%
EPS - - - 0.0700 0.0500 - 0.4900 0.1900 0.3400 0.3200
Dividend per Share - - - - - - - - - -
Announcement Date 29/03/21 24/08/21 28/03/22 23/08/22 22/03/23 16/08/23 16/08/23 20/03/24 - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - 32,181 41,789 45,764 - 20,916 28,414 34,683
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - 3,662 2,921 5,865 - 4,656 6,237 8,161
ROE (net income / shareholders' equity) - 3.86% -2.71% 0.9% - 5.88% 6.93% 7.96%
ROA (Net income/ Total Assets) - 2.85% -2.33% 0.7% - 3.08% 3.87% 4.33%
Assets 1 - -605,613 45,998 54,639 - 78,243 82,229 94,934
Book Value Per Share 2 - 17.80 12.90 14.40 - 16.50 17.90 19.70
Cash Flow per Share 2 - 1.680 1.110 1.880 - 1.570 1.940 2.220
Capex 1 - 37.6 502 40.2 - 187 209 221
Capex / Sales - 0.19% 1.64% 0.09% - 0.3% 0.29% 0.26%
Announcement Date 25/11/20 29/03/21 28/03/22 22/03/23 20/03/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
24.62 CNY
Average target price
40.01 CNY
Spread / Average Target
+62.51%
Consensus
  1. Stock Market
  2. Equities
  3. 6618 Stock
  4. Financials JD Health International Inc.